domingo, 6 de diciembre de 2015

Dabrafenib - National Cancer Institute

Dabrafenib - National Cancer Institute

National Cancer Institute


  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
This page contains brief information about dabrafenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
FDA Approved

Use in Cancer

Dabrafenib is approved to be used alone or with trametinib to treat:
Dabrafenib is also being studied in the treatment of other types of cancer.

More About Dabrafenib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Dabrafenib - A lay language summary of important information about this drug that may include the following:
  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Targeted Cancer Therapies - Information about the use of this drug to treat cancer.

Research Results

Clinical Trial Results: Combining Two Types of Targeted Therapy Improves Survival in Some Patients With Advanced Melanoma - Important clinical trial results for this drug, background information, and how the trial was done.
New Therapies Are Changing the Outlook for Advanced Melanoma - Information from NCI about this drug.
MEK: A Single Drug Target Shows Promise in Multiple Cancers - Information from NCI about this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Dabrafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.

No hay comentarios:

Publicar un comentario